Sector ratings Charles River Laboratories International, Inc.

Equities

Market Closed - Nyse Other stock markets 21:00:02 15/01/2026 GMT			5-day change	1st Jan Change
223.47 ^USD	+3.27%		+3.69%	+12.03%

12:30pm	Citigroup Adjusts Price Target on Charles River Laboratories International to $265 From $200, Maintains Buy Rating	MT
01-13	Charles River Laboratories International, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 10:30 AM

Sector:

Location:

X axis:

Main competitors

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Capi.($)	Investor	ESG MSCI	Fundamentals	Financial revisions	Global Valuation	Visibility	Consensus
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	11B		A
LONZA GROUP AG	49.36B		AAA
IQVIA HOLDINGS INC.	41.09B		AAA
BEONE MEDICINES AG	37.43B		-
CELLTRION, INC.	31.37B		A
REVOLUTION MEDICINES, INC.	23.83B	-	B	-		-
REGENCELL BIOSCIENCE HOLDINGS LIMITED	14.86B	-	-	-	-	-	-	-
MEDPACE HOLDINGS, INC.	17.41B		BBB
EUROFINS SCIENTIFIC SE	14.86B		AA
ICON PUBLIC LIMITED COMPANY	13.94B		AA
ASCENDIS PHARMA A/S	13.2B	-	-	-		-
IONIS PHARMACEUTICALS, INC.	12.51B	-	A	-		-
TEMPUS AI, INC.	12.26B	-	A	-		-
BIO-TECHNE CORPORATION	10.9B		A
ABIVAX	9.36B	-	BBB	-		-
QIAGEN N.V.	9.97B		AAA
BLUEPRINT MEDICINES CORPORATION	8.38B	-	BB	-		-	-	-
PRAXIS PRECISION MEDICINES, INC.	8.26B	-	B	-		-
PHARMARON BEIJING CO., LTD.	7.85B		AA
HANGZHOU TIGERMED CONSULTING CO., LTD	7.44B		AAA
Average	17.76B		AA
Weighted average by Cap.			AA